Daily Aspirin Treatment After Preeclampsia

Part of paid clinical trials in Iowa City, Iowa.

Sponsor
Anna Stanhewicz, PhD
Study ID
NCT06168461
Phase
EARLY_PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Preeclampsia

Eligibility Criteria

Sex
FEMALE
Age
18 Years - 50 Years
Healthy Volunteers
Not accepted

Interventions

  • Aspirin — DRUG
    162mg aspirin capsule
  • Placebo — DRUG
    placebo capsule

Study Details

Women who develop preeclampsia during pregnancy are four times more likely to develop cardiovascular disease later in life, even if they are otherwise healthy. The reason why this occurs may be related to lasting blood vessel damage after the pregnancy but there are currently no specific treatment strategies to prevent this disease progression. This study addresses this public health issue by examining whether starting low dose aspirin therapy after pregnancy is an effective treatment for lasting blood vessel damage in order to inform better clinical management of cardiovascular disease risk in women who have had preeclampsia.

Key Dates

Start date
Nov 1, 2023
Status verified
Dec 2025
Primary completion
Jun 30, 2026
Completion
Jun 30, 2026

Study Design

Enrollment
40 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE

Arms

  • Placebo Comparator: placebo
    placebo pill taken once daily at bedtime for 12 weeks
  • Experimental: aspirin
    162mg aspirin taken once daily at bedtime for 12 weeks

Primary Outcome Measure

magnitude of microvascular endothelial function [ Time Frame: baseline, 12 weeks ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of IowaIowa CityIowa52242
Anna Stanhewicz
[email protected]
319-467-1732

Find similar trials in Iowa City, IA

By research site
University of Iowa· Iowa City, IA

Related Studies